SCHEMBL9892859

SCHEMBL9892859

CCC(=O)Nc1nc(-c2ccccc2)c(CC)s1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.81
HSD17B10 Q99714 4/20 0.77
HPGD P15428 1/20 0.77
TSHR P16473 1/20 0.77
MAPT P10636 5/20 0.67
RORC P51449 5/20 0.66
SMN1; SMN2 Q16637 2/20 0.56
NPC1 O15118 1/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 1/20 0.56
MAPK1 P28482 1/20 0.54
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
GAA P10253 2/20 0.51
PTGDR2 Q9Y5Y4 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14960379 0.87 ALDH1A1 (0.74) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL2753574 0.84 RORC (0.65) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL9891524 0.84 ALDH1A1 (0.69) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL9891918 0.84 ALDH1A1 (0.69) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL24026376 0.83 ALDH1A1 (0.57) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL3609977 0.81 ALDH1A1 (0.64) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL1914796 0.79 ALDH1A1 (0.62) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL1915738 0.79 ALDH1A1 (0.62) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL2122638 0.79 ALDH1A1 (0.62) ALDH1A1HSD17B10HPGDTSHRMAPT
SCHEMBL18113867 0.79 ALDH1A1 (0.62) ALDH1A1HSD17B10HPGDTSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889670-B2 Heterocyclic compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 US disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ALDH1A1 1724/4885HSD17B10 3696/4885HPGD 803/4885
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ALDH1A1 2533/4885HSD17B10 2211/4885HPGD 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.